This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Back to Drug Candidates

Dichloroacetate (DCA)

Pyruvate dehydrogenase kinase inhibitor

Evidence Score

35

preclinical
Mechanism of Action

Inhibits PDK1-4, reactivating pyruvate dehydrogenase and forcing pyruvate into the TCA cycle. In SDH-deficient cells, this pushes metabolites into a broken TCA cycle, potentially increasing ROS and triggering apoptosis.

Pathway Connections
Pseudohypoxia / HIF Pathway

Succinate accumulation inhibits PHD enzymes, stabilizing HIF-1α and HIF-2α regardless of oxygen levels. This drives angiogenesis (VEGF), metabolic reprogramming (glycolysis shift), and growth factor signaling.

Upstream event:

Succinate inhibits PHD1/2/3 (α-KG-dependent dioxygenases)

Downstream effects:

HIF-1α/2α stabilizationVEGF upregulationGLUT1/3 upregulationGlycolytic enzyme inductionEPO production
Oxidative Stress / ROS

Complex II dysfunction causes electron leak in the electron transport chain, increasing reactive oxygen species (ROS). This drives DNA damage but also creates a therapeutic vulnerability.

Upstream event:

Impaired electron flow through Complex II → electron leak

Downstream effects:

Increased ROS productionOxidative DNA damageGenomic instabilityPARP activation for DNA repairTherapeutic vulnerability to further ROS stress
Molecular Targets

PDK1

Pyruvate dehydrogenase kinase 1

downstream

HIF target that suppresses pyruvate entry into TCA cycle, reinforcing glycolytic shift. Target of dichloroacetate (DCA).

UniProt: Q15118

Quick Facts
Not FDA Approved
ChEMBL IDCHEMBL1213352
PubChem CID54675
Evidence

Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.

Coming in Phase 3

For research exploration only — not medical advice. Consult your doctor before acting on any information.

AI Analysis

Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.